Dexamethasone for ocular inflammation

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 7, 2011, Pages 1127-1131

  Saraiya, Nehali V ^a   Goldstein, Debra A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Dexamethasone; implant; inflammation; intermediate; posterior; steroid; uveitis

Indexed keywords

DEXAMETHASONE;

ARTICLE; DRUG EFFICACY; DRUG IMPLANT; DRUG SAFETY; EYE INFLAMMATION; HUMAN; INTRAOCULAR HYPERTENSION; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); UVEITIS; VISUAL ACUITY;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; CATARACT; DEXAMETHASONE; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; HUMANS; INFLAMMATION; INJECTIONS; UVEITIS; VISION, OCULAR; VISUAL ACUITY; VITREOUS BODY;

EID: 79953857353     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.571209     Document Type: Article

References (22)

1. Nussenblatt RB. The natural history of uveitis. Int Ophthalmol 1990;14:303-8 (Pubitemid 20350862)
2. Goldstein H. The reported demography and causes of blindness throughout the world. Adv Ophthalmol 1980;12:1-99
3. Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 1996;80:844-8 (Pubitemid 26345317)
4. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California: the Northern California Epidemiology of Uveitis Study. Ophthalmology 2004;113:491-500 (Pubitemid 38293104)
5. Durrani OM, Tehrani NM, Marr JE, et al. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol 2004;88:1159-62 (Pubitemid 39141376)
6. Weiner A, BenEzra D. Clinical patterns and associated conditions in chronic uveitis. Am J Ophthalmol 1991;112:151-8
7. Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996;80:332-6 (Pubitemid 26113585)
8. Anglade E, Whitcup SM. The diagnosis and management of uveitis. Drugs 1995;49:213-23
9. Hauper CL, Jaffe GJ. New and emerging treatments for patients with uveitis. Int Ophthalmol Clin 2000;40:205-20 (Pubitemid 30235950)
10. Antcliff RJ, Spalton DJ, Stanford MR, et al. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 2001;108:765-72 (Pubitemid 32238474)
11. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003;110:681-6 (Pubitemid 36520063)
12. Audren F, Tom M, Massin P, et al. Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci 2004;45:3435-41 (Pubitemid 39298559)
13. Callanan DG, Jaffe GJ, Martin DF, et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 2008;126:1191-201
14. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 2007;124:309-17 (Pubitemid 46425557)
15. Williams GA, Haller JA, Kuppermann BD, et al. Dexamethasone DDS Phase II Study Group. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 2009;147:1048-54
16. Lowder CY, Belfort R, Lightman S, et al. for the Ozurdex HURON Study Group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol Jan 2011. [Epub ahead of print]
17. Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and Pharmacodynamics of the sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011;52(1):80-6
18. Naik RK, Gelhorn H, Kowalski J, et al. Efficacy of dexamethasone intravitreal implant for the treatment of uveitis based on patient-reported vision function outcome measures. ARVO abstract 5875/A2, May 2010
19. Sallam A, Sheth HG, Habot-Wilner Z, et al. Outcome of raised intraocular pressure in uveitic eyes with and without a corticosteroid-induced hypertensive response. Am J Ophthalmol 2009;148:207-13
20. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-46
21. Phase III Study Results of OZURDEX™ in the Treatment of Macular Edema Due to Branch and Central Retinal Vein Occlusion 6-Month Open Label Follow-Up. Data courtesy of Allergan Medical Affairs.
22. Goldstein DA, Godfrey DG, Hall A, et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol 2007;125:1478-85 (Pubitemid 350106679)